Reference data : LOINC code

Filter


Clear filter

Results
104,672 results found
Loinc Number Component Property System Time aspect ScaleType MethodType Relat_nms loincStatus Long Common name answerList chngType <span class='defaultText'>DefinitionDescription</span> dtLastCh exactCmspy exampleUnits exmplAnswers externalCopyrightNotice formula hl7FieldSubfieldId InpcPercentage ipccUnits loincClass loincFinal loincNum mapTo methodTyp molarMass naaccrId orderObs panelElements reference scope setRoot shortName source surveyQuestSrc surveyQuestText unitsRequired acssym relatedNames2 VersionLastChanged VersionFirstRelease ValidHL7AttachmentRequest PanelType AssociatedObservations EXTERNAL_COPYRIGHT_LINK HL7_ATTACHMENT_STRUCTURE CONSUMER_NAME EXAMPLE_UCUM_UNITS STATUS_REASON STATUS_TEXT CHANGE_REASON_PUBLIC COMMON_TEST_RANK COMMON_ORDER_RANK
25220-5 cefOXitin 30.0 ug/mL Susc Isolate Pt OrdQn Method for Slow-growing mycobacteria &nbsp; ACTIVE cefOXitin 30 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria &nbsp; MIN DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ABXBACT &nbsp; 25220-5 &nbsp; Method for Slow-growing mycobacteria &nbsp; &nbsp; Observation &nbsp; &nbsp; &nbsp; 0 cefOXitin 30 ug/mL Islt SlowMyco &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 30 ug/mL; AFB; ANTIBIOTIC SUSCEPTIBILITIES; AST; ID; Infectious Disease; InfectiousDisease; Islt; Isol; mcg; Mefj; Mefoxin; Myco; Mycobacteria susceptibility; Mycobacterial susceptibility; Point in time; Random; SlowMyco; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty; TB; Tuberculosis 2.26 2 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0
25221-3 Imipenem 10.0 ug/mL Susc Isolate Pt OrdQn Method for Slow-growing mycobacteria &nbsp; ACTIVE Imipenem 10 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria &nbsp; MIN DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ABXBACT &nbsp; 25221-3 &nbsp; Method for Slow-growing mycobacteria &nbsp; &nbsp; Observation &nbsp; &nbsp; &nbsp; 0 Imipenem 10 ug/mL Islt SlowMyco &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 10 ug/mL; AFB; ANTIBIOTIC SUSCEPTIBILITIES; AST; ID; Imipeneum; Imp; Infectious Disease; InfectiousDisease; Islt; Isol; mcg; Myco; Mycobacteria susceptibility; Mycobacterial susceptibility; Point in time; Primaxin; Random; SlowMyco; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty; TB; Tuberculosis 2.26 2 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0
25222-1 Cefmetazole 30.0 ug/mL Susc Isolate Pt OrdQn Method for Slow-growing mycobacteria &nbsp; ACTIVE Cefmetazole 30 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria &nbsp; MIN DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ABXBACT &nbsp; 25222-1 &nbsp; Method for Slow-growing mycobacteria &nbsp; &nbsp; Observation &nbsp; &nbsp; &nbsp; 0 Cefmetazole 30 ug/mL Islt SlowMyco &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 30 ug/mL; AFB; ANTIBIOTIC SUSCEPTIBILITIES; AST; Cefmetazon; Cemetol; ID; Infectious Disease; InfectiousDisease; Islt; Isol; mcg; Myco; Mycobacteria susceptibility; Mycobacterial susceptibility; Point in time; Random; SlowMyco; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty; TB; Tuberculosis; Zefazone 2.26 2 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0
25223-9 Doxycycline 30.0 ug/mL Susc Isolate Pt OrdQn Method for Slow-growing mycobacteria &nbsp; ACTIVE Doxycycline 30 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria &nbsp; MIN DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ABXBACT &nbsp; 25223-9 &nbsp; Method for Slow-growing mycobacteria &nbsp; &nbsp; Observation &nbsp; &nbsp; &nbsp; 0 Doxycycline 30 ug/mL Islt SlowMyco &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 30 ug/mL; AFB; ANTIBIOTIC SUSCEPTIBILITIES; AST; c206; c216; ID; Infectious Disease; InfectiousDisease; Islt; Isol; mcg; Myco; Mycobacteria susceptibility; Mycobacterial susceptibility; Point in time; Random; SlowMyco; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty; TB; Tuberculosis; Vibramycin 2.26 2 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0
25224-7 Erythromycin 15.0 ug/mL Susc Isolate Pt OrdQn Method for Slow-growing mycobacteria &nbsp; ACTIVE Erythromycin 15 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria &nbsp; MIN DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ABXBACT &nbsp; 25224-7 &nbsp; Method for Slow-growing mycobacteria &nbsp; &nbsp; Observation &nbsp; &nbsp; &nbsp; 0 Erythromycin 15 ug/mL Islt SlowMyco &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 15 ug/mL; AFB; ANTIBIOTIC SUSCEPTIBILITIES; AST; c212; EES; Erygel; Erythromycn; ID; Ilosone; Ilotycin; Iltycin; Infectious Disease; InfectiousDisease; Islt; Isol; mcg; Myco; Mycobacteria susceptibility; Mycobacterial susceptibility; Point in time; Random; SlowMyco; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty; TB; Tuberculosis 2.26 2 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0
25225-4 Minocycline 30.0 ug/mL Susc Isolate Pt OrdQn Method for Slow-growing mycobacteria &nbsp; ACTIVE Minocycline 30 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria &nbsp; MIN DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ABXBACT &nbsp; 25225-4 &nbsp; Method for Slow-growing mycobacteria &nbsp; &nbsp; Observation &nbsp; &nbsp; &nbsp; 0 Minocycline 30 ug/mL Islt SlowMyco &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 30 ug/mL; AFB; Aknemin; ANTIBIOTIC SUSCEPTIBILITIES; AST; c128; Dentomycin; ID; Infectious Disease; InfectiousDisease; Islt; Isol; Klinomysin; Lederderm; mcg; Mestacine; Mino-50; Minocin; Minomycin; Myco; Mycobacteria susceptibility; Mycobacterial susceptibility; Mynocine; Point in time; Random; SlowMyco; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty; TB; Tuberculosis 2.26 2 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0
25226-2 sulfiSOXAZOLE 300.0 ug/mL Susc Isolate Pt OrdQn Method for Slow-growing mycobacteria &nbsp; ACTIVE sulfiSOXAZOLE 300 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria &nbsp; MIN DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ABXBACT &nbsp; 25226-2 &nbsp; Method for Slow-growing mycobacteria &nbsp; &nbsp; Observation &nbsp; &nbsp; &nbsp; 0 Sulfisoxaz 300 ug/mL Islt SlowMyco &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 300 ug/mL; AFB; ANTIBIOTIC SUSCEPTIBILITIES; AST; Gantrisin; ID; Infectious Disease; InfectiousDisease; Islt; Isol; mcg; Myco; Mycobacteria susceptibility; Mycobacterial susceptibility; Point in time; Random; SlowMyco; Sulfizole; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty; TB; Tuberculosis 2.26 2 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0
25227-0 Tobramycin 10.0 ug/mL Susc Isolate Pt OrdQn Method for Slow-growing mycobacteria &nbsp; ACTIVE Tobramycin 10 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria &nbsp; MIN DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ABXBACT &nbsp; 25227-0 &nbsp; Method for Slow-growing mycobacteria &nbsp; &nbsp; Observation &nbsp; &nbsp; &nbsp; 0 Tobramycin 10 ug/mL Islt SlowMyco &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 10 ug/mL; AFB; Aminoglycosides; ANTIBIOTIC SUSCEPTIBILITIES; AST; ID; Infectious Disease; InfectiousDisease; Islt; Isol; mcg; Myco; Mycobacteria susceptibility; Mycobacterial susceptibility; NEBCIN; NEBDIN; Point in time; Random; SlowMyco; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty; TB; TOBJ; TOBRA; Tuberculosis 2.26 2 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0
25228-8 Vancomycin 30.0 ug/mL Susc Isolate Pt OrdQn Method for Slow-growing mycobacteria &nbsp; ACTIVE Vancomycin 30 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria &nbsp; MIN DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ABXBACT &nbsp; 25228-8 &nbsp; Method for Slow-growing mycobacteria &nbsp; &nbsp; Observation &nbsp; &nbsp; &nbsp; 0 Vancomycin 30 ug/mL Islt SlowMyco &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 30 ug/mL; AFB; ANTIBIOTIC SUSCEPTIBILITIES; AST; c162; ID; Infectious Disease; InfectiousDisease; Islt; Isol; mcg; Myco; Mycobacteria susceptibility; Mycobacterial susceptibility; Point in time; Random; SlowMyco; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty; TB; Tuberculosis; VANC; Vancocin; Vancor 2.26 2 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0
25229-6 Pyrazinamide 100.0 ug/mL Susc Isolate Pt OrdQn Method for Slow-growing mycobacteria &nbsp; ACTIVE Pyrazinamide 100 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria &nbsp; MIN DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ABXBACT &nbsp; 25229-6 &nbsp; Method for Slow-growing mycobacteria &nbsp; &nbsp; Observation &nbsp; &nbsp; &nbsp; 0 PZA 100 ug/mL Islt SlowMyco &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 100 ug/mL; AFB; ANTIBIOTIC SUSCEPTIBILITIES; AST; ID; Infectious Disease; InfectiousDisease; Islt; Isol; mcg; Myco; Mycobacteria susceptibility; Mycobacterial susceptibility; Point in time; PZA; Random; SlowMyco; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty; TB; Tuberculosis 2.73 2 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0
2523-9 Lactate SCnc Periton fld Pt Qn &nbsp; &nbsp; ACTIVE Lactate [Moles/volume] in Peritoneal fluid &nbsp; MIN DefinitionDescription &nbsp; &nbsp; mmol/L &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; CHEM &nbsp; 2523-9 &nbsp; &nbsp; &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 Lactate Prt-sCnc &nbsp; &nbsp; &nbsp; Y &nbsp; 2-Hydroxypropanoic acid; 2-hydroxy-propionate; 2-hydroxy-propionic acid; Ascites; Ascitic fluid; Ascitis; Chemistry; Lact; Lactic acid; Level; L-lactate; Peritoneal fluid; Point in time; Prt; QNT; Quan; Quant; Quantitative; Random; Substance concentration 2.73 1 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; mmol/L &nbsp; &nbsp; &nbsp; 0
25230-4 Ethambutol 2.5 ug/mL Susc Isolate Pt OrdQn Method for Slow-growing mycobacteria &nbsp; ACTIVE Ethambutol 2.5 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria &nbsp; MIN DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ABXBACT &nbsp; 25230-4 &nbsp; Method for Slow-growing mycobacteria &nbsp; &nbsp; Observation &nbsp; &nbsp; &nbsp; 0 Ethambutol 2.5 ug/mL Islt SlowMyco &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; AFB; ANTIBIOTIC SUSCEPTIBILITIES; AST; Etambol; Ethamb; ID; Inagen; Infectious Disease; InfectiousDisease; Islt; Isol; mcg; Myambutol; Myco; Mycobacteria susceptibility; Mycobacterial susceptibility; Mycobutol; Olbutam; Point in time; Random; SlowMyco; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty; TB; Tuberculosis 2.73 2 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0
25231-2 Ethionamide 10.0 ug/mL Susc Isolate Pt OrdQn Method for Slow-growing mycobacteria &nbsp; ACTIVE Ethionamide 10 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria &nbsp; MIN DefinitionDescription &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ABXBACT &nbsp; 25231-2 &nbsp; Method for Slow-growing mycobacteria &nbsp; &nbsp; Observation &nbsp; &nbsp; &nbsp; 0 Ethionamide 10 ug/mL Islt SlowMyco &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 10 ug/mL; AFB; ANTIBIOTIC SUSCEPTIBILITIES; AST; ID; Infectious Disease; InfectiousDisease; Islt; Isol; mcg; Myco; Mycobacteria susceptibility; Mycobacterial susceptibility; Point in time; Random; SlowMyco; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty; TB; Trecator; Tuberculosis 2.73 2 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0
25232-0 Nafcillin MCnc XXX Pt Qn &nbsp; &nbsp; ACTIVE Nafcillin [Mass/volume] in Specimen &nbsp; MIN DefinitionDescription &nbsp; &nbsp; ug/mL &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; DRUG/TOX &nbsp; 25232-0 &nbsp; &nbsp; &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 Nafcillin Spec-mCnc &nbsp; &nbsp; &nbsp; Y &nbsp; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Misc; Miscellaneous; NAFJ; Other; Point in time; QNT; Quan; Quant; Quantitative; Random; Spec; To be specified in another part of the message; Unipen; Unspecified 2.7 2 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ug/mL &nbsp; &nbsp; &nbsp; 0
25233-8 Azithromycin MCnc XXX Pt Qn &nbsp; &nbsp; ACTIVE Azithromycin [Mass/volume] in Specimen &nbsp; MIN DefinitionDescription &nbsp; &nbsp; ug/mL &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; DRUG/TOX &nbsp; 25233-8 &nbsp; &nbsp; &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 Azithromycin Spec-mCnc &nbsp; &nbsp; &nbsp; Y &nbsp; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Misc; Miscellaneous; Other; Point in time; QNT; Quan; Quant; Quantitative; Random; Spec; To be specified in another part of the message; Unspecified; Zithromax 2.7 2 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ug/mL &nbsp; &nbsp; &nbsp; 0
25234-6 Aztreonam MCnc XXX Pt Qn &nbsp; &nbsp; ACTIVE Aztreonam [Mass/volume] in Specimen &nbsp; MIN DefinitionDescription &nbsp; &nbsp; ug/mL &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; DRUG/TOX &nbsp; 25234-6 &nbsp; &nbsp; &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 Aztreonam Spec-mCnc &nbsp; &nbsp; &nbsp; Y &nbsp; Azactam; Azaj; azthreonam; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Misc; Miscellaneous; Other; Point in time; QNT; Quan; Quant; Quantitative; Random; Spec; To be specified in another part of the message; Unspecified 2.73 2 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ug/mL &nbsp; &nbsp; &nbsp; 0
25235-3 ceFAZolin MCnc XXX Pt Qn &nbsp; &nbsp; ACTIVE ceFAZolin [Mass/volume] in Specimen &nbsp; MIN DefinitionDescription &nbsp; &nbsp; ug/mL &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; DRUG/TOX &nbsp; 25235-3 &nbsp; &nbsp; &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 ceFAZolin Spec-mCnc &nbsp; &nbsp; &nbsp; Y &nbsp; Ancef; C32; Cefamezin; DRUG/TOXICOLOGY; Drugs; Kefj; Kefzol; Level; Mass concentration; Misc; Miscellaneous; Other; Point in time; QNT; Quan; Quant; Quantitative; Random; Spec; To be specified in another part of the message; Totacef; Unspecified; Zolicef 2.73 2 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ug/mL &nbsp; &nbsp; &nbsp; 0
25236-1 Cefixime MCnc XXX Pt Qn &nbsp; &nbsp; ACTIVE Cefixime [Mass/volume] in Specimen &nbsp; MIN DefinitionDescription &nbsp; &nbsp; ug/mL &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; DRUG/TOX &nbsp; 25236-1 &nbsp; &nbsp; &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 Cefixime Spec-mCnc &nbsp; &nbsp; &nbsp; Y &nbsp; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Misc; Miscellaneous; Other; Point in time; QNT; Quan; Quant; Quantitative; Random; Spec; Suprax; To be specified in another part of the message; Unspecified 2.7 2 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ug/mL &nbsp; &nbsp; &nbsp; 0
25237-9 Cefonicid MCnc XXX Pt Qn &nbsp; &nbsp; ACTIVE Cefonicid [Mass/volume] in Specimen &nbsp; MIN DefinitionDescription &nbsp; &nbsp; ug/mL &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; DRUG/TOX &nbsp; 25237-9 &nbsp; &nbsp; &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 Cefonocid Spec-mCnc &nbsp; &nbsp; &nbsp; Y &nbsp; Cefonocid; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Misc; Miscellaneous; Monocid; Other; Point in time; QNT; Quan; Quant; Quantitative; Random; Spec; To be specified in another part of the message; Unspecified 2.7 2 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ug/mL &nbsp; &nbsp; &nbsp; 0
25238-7 Cefotaxime MCnc XXX Pt Qn &nbsp; &nbsp; ACTIVE Cefotaxime [Mass/volume] in Specimen &nbsp; MIN DefinitionDescription &nbsp; &nbsp; ug/mL &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; DRUG/TOX &nbsp; 25238-7 &nbsp; &nbsp; &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 Cefotaxime Spec-mCnc &nbsp; &nbsp; &nbsp; Y &nbsp; Claforan; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Misc; Miscellaneous; Other; Point in time; QNT; Quan; Quant; Quantitative; Random; Spec; To be specified in another part of the message; Unspecified 2.7 2 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ug/mL &nbsp; &nbsp; &nbsp; 0
25239-5 cefoTEtan MCnc XXX Pt Qn &nbsp; &nbsp; ACTIVE cefoTEtan [Mass/volume] in Specimen &nbsp; MIN DefinitionDescription &nbsp; &nbsp; ug/mL &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; DRUG/TOX &nbsp; 25239-5 &nbsp; &nbsp; &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 cefoTEtan Spec-mCnc &nbsp; &nbsp; &nbsp; Y &nbsp; Cefotan; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Misc; Miscellaneous; Other; Point in time; QNT; Quan; Quant; Quantitative; Random; Spec; To be specified in another part of the message; Unspecified 2.7 2 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ug/mL &nbsp; &nbsp; &nbsp; 0
2524-7 Lactate SCnc Ser/Plas Pt Qn &nbsp; &nbsp; ACTIVE Lactate [Moles/volume] in Serum or Plasma &nbsp; MIN DefinitionDescription &nbsp; &nbsp; mmol/L &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; CHEM &nbsp; 2524-7 &nbsp; &nbsp; &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 Lactate SerPl-sCnc &nbsp; &nbsp; &nbsp; Y &nbsp; 2-Hydroxypropanoic acid; 2-hydroxy-propionate; 2-hydroxy-propionic acid; Chemistry; Lact; Lactic acid; Level; L-lactate; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration; UniversalLabOrders 2.73 1 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; mmol/L &nbsp; &nbsp; &nbsp; 136
25240-3 cefOXitin MCnc XXX Pt Qn &nbsp; &nbsp; ACTIVE cefOXitin [Mass/volume] in Specimen &nbsp; MIN DefinitionDescription &nbsp; &nbsp; ug/mL &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; DRUG/TOX &nbsp; 25240-3 &nbsp; &nbsp; &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 cefOXitin Spec-mCnc &nbsp; &nbsp; &nbsp; Y &nbsp; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Mefj; Mefoxin; Misc; Miscellaneous; Other; Point in time; QNT; Quan; Quant; Quantitative; Random; Spec; To be specified in another part of the message; Unspecified 2.73 2 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ug/mL &nbsp; &nbsp; &nbsp; 0
25241-1 Cefpodoxime MCnc XXX Pt Qn &nbsp; &nbsp; ACTIVE Cefpodoxime [Mass/volume] in Specimen &nbsp; MIN DefinitionDescription &nbsp; &nbsp; ug/mL &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; DRUG/TOX &nbsp; 25241-1 &nbsp; &nbsp; &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 Cefpodoxime Spec-mCnc &nbsp; &nbsp; &nbsp; Y &nbsp; Cefodox; Cefpodoxime proxetil; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Misc; Miscellaneous; Orelox; Other; Podomexef; Point in time; QNT; Quan; Quant; Quantitative; Random; Spec; To be specified in another part of the message; Unspecified; Vantin 2.7 2 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ug/mL &nbsp; &nbsp; &nbsp; 0
25242-9 Cefsulodin MCnc XXX Pt Qn &nbsp; &nbsp; ACTIVE Cefsulodin [Mass/volume] in Specimen &nbsp; MIN DefinitionDescription &nbsp; &nbsp; ug/mL &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; DRUG/TOX &nbsp; 25242-9 &nbsp; &nbsp; &nbsp; &nbsp; Both &nbsp; &nbsp; &nbsp; 0 Cefsulodin Spec-mCnc &nbsp; &nbsp; &nbsp; Y &nbsp; Cefsulodine; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Misc; Miscellaneous; Monaspor; Other; Point in time; Pseudocef; Pyocefal; QNT; Quan; Quant; Quantitative; Random; Spec; Sulcephalosporin; Takesulin; To be specified in another part of the message; Unspecified 2.7 2 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ug/mL &nbsp; &nbsp; &nbsp; 0
104,672 results found